Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy Cancer Sensitizing Agents for Chemotherapy Series
Directeur de Collection : Bonavida Benjamin
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials.
1. EGFR and HER2 inhibitors as sensitizing agents for cancer chemotherapy2. BCR-ABL inhibitors as sensitizing agents for cancer chemotherapy3. VEGFR inhibitors as sensitizing agents for cancer chemotherapy4. ALK inhibitors as sensitizing agents for cancer chemotherapy5. JAK2 inhibitors as sensitizing agents for cancer chemotherapy6. FLT3 inhibitors as sensitizing agents for cancer chemotherapy7. BRAF inhibitors as sensitizing agents for cancer chemotherapy8. Bruton kinase inhibitors as sensitizing agents for cancer chemotherapy
cancer researchers; oncologists; pharmacists; graduate students on cancer studies
Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
- Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research
- Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms
- Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment
Date de parution : 11-2018
Ouvrage de 292 p.
19x23.3 cm
Thèmes de Protein Kinase Inhibitors as Sensitizing Agents for... :
Mots-clés :
ABC drug transporters; ABC transporters; Acute myeloid leukemia; Akt; Anaplastic lymphoma kinase; Antiapoptotic proteins; Apoptosis; ATP-binding cassette; Autophagy; Bcl-2; BCR-ABL gene; BCR-ABL inhibitors; Bevacizumab; BH3 mimetic; BH3-only proteins; BRAF; Breast cancer; Bruton’s tyrosine kinase inhibitor; Cancer; Cancer chemotherapy; Cancer therapy; Chemoresistance; Chemosensitizer; Chemotherapy; Chronic myeloid leukemia; Collagen; Combination; Crenolanib; Cyclin-dependent kinases (CDKs); DDR inhibitors; DDR1; DDR2; DNA-binding domain; Drug; EGFR; FLT3; Gilteritinib; HER2; Ibrutinib; Inhibitor; Janus kinase; MDM2 inhibitor; MDMX inhibitor; MDR reversing agent; Midostaurin; mTOR; Multidrug resistance; Multiple drug resistance; Mutant p53; Natural products; NSCLC; p53 reactivation; Pancreatic ductal adenocarcinoma; PI3K; PI3K/Akt; Polo-like kinase 1; Ponatinib; Proapoptotic proteins; Proteasome inhibitors; Protein kinase inhibitors; Quizartinib; Ramucirumab; Resistance; Retinoblastoma protein; Sensitization; Sensitizer; Sensitizing agent; Sensitizing agents; SH2 domain; Sorafenib; SPARC; STAT3 inhibitor; Sunitinib; Synthesized compounds; Tumor angiogenesis inhibitor; Tyrosine kinase inhibitors; Tyrosine kinase inhibitorsPlease check whether the inserted are appropriate as given.-->; VEGFR
